Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Canaccord Genuity's Edward Nash raised their price target on Ventyx Biosciences (NASDAQ: VTYX) by 14.3% from $14 to $16 on 2025/11/08. The analyst maintained their Strong Buy rating on the stock.

Ventyx Biosciences reported its Q3 2025 earnings.

Nash attributed their price target hike to (1) their reduced near-term Opex projections based on the company's latest financial results, and (2) the clinical development status of the company's pipeline with fewer clinical trials currently ongoing, compared to Q1 and Q2 2025.

Earnings Report

For Q3 2025, Ventyx Biosciences reported:

EPS of $(0.32), which beat the consensus estimate of $(0.45).

Revenue of $0.00.

Management did not provide financial guidance in its press release.

CEO Raju Mohan, PhD, commented: “I am proud of the Ventyx team for achieving two key milestones this year, generating data from the Phase 2a study with our CNS penetrant NLRP3 inhibitor VTX3232 in patients with early Parkinson’s disease and, more recently, data from the VTX3232 Phase 2 study in participants with obesity and cardiovascular risk factors.

"Key takeaways from the latter study were hsCRP levels were reduced by nearly 80% and, additionally, we saw significant reductions in IL-6, hsCRP, Lp(a) and other markers of systemic inflammation.

“Earlier in the year, we reported data showing that treatment with VTX3232 yields significant reductions in NLRP3-mediated biomarkers in the plasma and CSF of patients with early Parkinson’s disease.

"These results position VTX3232 as a next-generation, oral therapy targeting inflammation in cardiovascular, neuroinflammatory and neurodegenerative diseases.

" We are looking forward to achieving our third major milestone of 2025 by reporting topline data from our Phase 2 study of VTX2735 in recurrent pericarditis during the fourth quarter.”